| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)
|
De Vita, F
|
|
|
18 |
8 |
p. 1354-1358
|
article
|
| 2 |
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
|
Beeram, M
|
|
|
18 |
8 |
p. 1323-1328
|
article
|
| 3 |
An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-α2b in patients with multiple myeloma maintained on a steady dose of interferon-α2b
|
Sirohi, B
|
|
|
18 |
8 |
p. 1388-1394
|
article
|
| 4 |
Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors
|
Hariharan, S
|
|
|
18 |
8 |
p. 1400-1407
|
article
|
| 5 |
Association between glycosylated hemoglobin and cancer risk: a New Zealand linkage study
|
Travier, N
|
|
|
18 |
8 |
p. 1414-1419
|
article
|
| 6 |
Breast cancer prognostication and prediction in the postgenomic era
|
Lønning, P.E.
|
|
|
18 |
8 |
p. 1293-1306
|
article
|
| 7 |
Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004
|
Arbyn, M
|
|
|
18 |
8 |
p. 1423-1425
|
article
|
| 8 |
Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study
|
Ferrandina, G
|
|
|
18 |
8 |
p. 1348-1353
|
article
|
| 9 |
Endocrine resistance in breast cancer: what really matters?
|
Dawood, S
|
|
|
18 |
8 |
p. 1289-1291
|
article
|
| 10 |
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer
|
Carles, J
|
|
|
18 |
8 |
p. 1359-1362
|
article
|
| 11 |
in this issue
|
|
|
|
18 |
8 |
p. 1287
|
article
|
| 12 |
Is avoiding post-mastectomy radiotherapy justified for patients with four or more involved axillary nodes and endocrine-responsive tumours? Lessons from a series in a single institution
|
Gentilini, O
|
|
|
18 |
8 |
p. 1342-1347
|
article
|
| 13 |
Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type
|
Kim, S.J.
|
|
|
18 |
8 |
p. 1382-1387
|
article
|
| 14 |
Lymphoma and human immunodeficiency virus (HIV) infection: another favourable setting?
|
Torresin, A
|
|
|
18 |
8 |
p. 1422-1423
|
article
|
| 15 |
New drug development in digestive neuroendocrine tumors
|
Durán, I
|
|
|
18 |
8 |
p. 1307-1313
|
article
|
| 16 |
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma
|
Hohaus, S
|
|
|
18 |
8 |
p. 1376-1381
|
article
|
| 17 |
Prognosis for long-term survivors of cancer
|
Janssen-Heijnen, M.L.G.
|
|
|
18 |
8 |
p. 1408-1413
|
article
|
| 18 |
Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations
|
Launay-Vacher, V
|
|
|
18 |
8 |
p. 1314-1321
|
article
|
| 19 |
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
|
El Gnaoui, T
|
|
|
18 |
8 |
p. 1363-1368
|
article
|
| 20 |
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
|
Beauclair, S
|
|
|
18 |
8 |
p. 1335-1341
|
article
|
| 21 |
Table of Contents
|
|
|
|
18 |
8 |
p. i-ii
|
article
|
| 22 |
The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study
|
Kelly, L
|
|
|
18 |
8 |
p. 1395-1399
|
article
|
| 23 |
The other side of p53
|
Ferretti, G
|
|
|
18 |
8 |
p. 1425-1426
|
article
|
| 24 |
Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer
|
Klaeser, B
|
|
|
18 |
8 |
p. 1329-1334
|
article
|
| 25 |
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group
|
Zervas, K
|
|
|
18 |
8 |
p. 1369-1375
|
article
|
| 26 |
Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells
|
Farace, F
|
|
|
18 |
8 |
p. 1421-1422
|
article
|
Journal description